Aardvark Therapeutics (NASDAQ:AARD) Posts Earnings Results

Aardvark Therapeutics (NASDAQ:AARD) issued its earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, FiscalAI reports.

Aardvark Therapeutics Price Performance

NASDAQ:AARD opened at $5.44 on Friday. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.94. The company has a 50-day moving average of $5.31 and a 200 day moving average of $9.99. The firm has a market cap of $118.70 million, a PE ratio of -1.69 and a beta of 5.11.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AARD shares. Morgan Stanley reissued an “equal weight” rating and set a $7.00 target price (down from $29.00) on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. B. Riley Financial started coverage on Aardvark Therapeutics in a report on Wednesday, January 28th. They issued a “buy” rating and a $32.00 price target for the company. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd. BTIG Research reiterated a “buy” rating and issued a $9.00 price target on shares of Aardvark Therapeutics in a report on Tuesday, March 24th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 price target on shares of Aardvark Therapeutics in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Institutional Trading of Aardvark Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC lifted its holdings in Aardvark Therapeutics by 5.9% during the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after buying an additional 76,151 shares during the period. Laurion Capital Management LP lifted its holdings in Aardvark Therapeutics by 6.1% during the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock worth $13,951,000 after buying an additional 60,653 shares during the period. Vanguard Group Inc. lifted its holdings in Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after buying an additional 94,744 shares during the period. Millennium Management LLC lifted its holdings in Aardvark Therapeutics by 51.2% during the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after buying an additional 163,717 shares during the period. Finally, SymBiosis Capital Partners LLC purchased a new stake in Aardvark Therapeutics during the fourth quarter worth $6,255,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.